The disclosure relates, in part, to methods of using pregnenolone sulfate (PREGS) to protect against the neurotoxicity of the β-amyloid peptide Aβ1-42. The disclosure also provides methods of using pegnanolone sulfate for treating neurologic disease or dysfunction. The disclosure further provides of using pegnanolone sulfate methods for stimulating or promoting growth of a neuronal cell.
